Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 23:06 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases
NCT05987176 · Imperial College London · PHASE2 · terminated · last registry update 2026-01-14 · Pancreatic cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study has closed earlier than planned due to one of the funders decision to withdraw the financial support for the study.” | – | Registry record, Imperial College London |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SSTR5 in pancreatic cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-02Phase 3 first posted: Tata Memorial Hospital, Capecitabine + Temozolomide (TMZ) (NCT07910760)
- 2026-09-25Phase 3 first posted: Washington University School of Medicine, Somatostatin Analogue(s) (NCT07842172)
- 2026-04-03Also stopped (suspended): Mayo Clinic, Somatostatin analog (NCT04329039)
- 2026-03-18Phase 3 first posted: Shanghai Zhongshan Hospital, Octreotide Microspheres + Placebo (NCT07479784)
- 2025-10-31Results posted on the registry: Crinetics Pharmaceuticals Inc., Randomized: 40 mg Paltusotine + Randomized: 80 mg Paltusotine (NCT05361668)
- 2025-09-10Phase 3 first posted: CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Sirolimus for injection (albumin bound) + Octreotide long-acting injection (NCT07165886)
- 2025-07-25Phase 3 first posted: Crinetics Pharmaceuticals Inc., Paltusotine + Placebo (NCT07087054)
- 2025-02-04Phase 3 first posted: SWOG Cancer Research Network, Lanreotide (NCT06807437)
- 2025-01-24Results posted on the registry: Advanced Accelerator Applications, arginine/lysine (NCT04524442)
- 2025-01-20Phase 3 first posted: Novartis Pharmaceuticals, Octreotide LAR (NCT06784752)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision